Endovascular NeuromoDulation Treatment fOr Heart Failure Patients (ENDO-HF)

NCT02633644 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-07-28

No results posted yet for this study

Summary

The purpose of the ENDO-HF study is to determine the safety \& performance of the Harmony System for the treatment of heart failure

Conditions

Interventions

DEVICE

Harmony System

Percutaneous neuromodulation of the aortic wall

Sponsors & Collaborators

  • Enopace Biomedical

    lead INDUSTRY

Principal Investigators

  • Daniel Weiss, MD · Enopace Biomedical

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2023-06-30

Countries

  • Belgium
  • Croatia
  • Greece
  • Israel

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02633644 on ClinicalTrials.gov